PATENT CLAIM ANALYSIS

Application Number: 15745639
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["514", "619000"]

Abstract:
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.

Claim (Index 7):
The method according to  claim 1 , wherein said ureidomustine is formulated as a pharmaceutical composition.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.46667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13394060', '14131423', '13260540', '15413267', '15320089']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7336644124355624
- 35 USC 102 Novelty (BERT): 0.4971214850746381
- Combined Prediction Score: 0.71001011969947
- Mean Citation Score: 167.370278
- Max Citation Score: 172.86093
- Similarity Product: 107.27567720297098

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test